|
|
|
|
| LEADER |
01221nam a2200337Ia 4500 |
| 001 |
10-1007-s00125-021-05623-z |
| 008 |
220420s2022 CNT 000 0 und d |
| 020 |
|
|
|a 0012186X (ISSN)
|
| 245 |
1 |
0 |
|a Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]
|
| 260 |
|
0 |
|b Springer Science and Business Media Deutschland GmbH
|c 2022
|
| 300 |
|
|
|a 4
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1007/s00125-021-05623-z
|
| 650 |
0 |
4 |
|a Body weight
|
| 650 |
0 |
4 |
|a Chronic kidney disease
|
| 650 |
0 |
4 |
|a Ertugliflozin
|
| 650 |
0 |
4 |
|a Estimated glomerular filtration rate
|
| 650 |
0 |
4 |
|a Kidney outcomes
|
| 650 |
0 |
4 |
|a Sodium–glucose cotransporter 2 inhibitor
|
| 700 |
1 |
0 |
|a Cannon, C.P.
|e author
|
| 700 |
1 |
0 |
|a Charbonnel, B.
|e author
|
| 700 |
1 |
0 |
|a Cherney, D.Z.I.
|e author
|
| 700 |
1 |
0 |
|a Cosentino, F.
|e author
|
| 700 |
1 |
0 |
|a Dagogo-Jack, S.
|e author
|
| 700 |
1 |
0 |
|a Frederich, R.
|e author
|
| 700 |
1 |
0 |
|a Maldonado, M.
|e author
|
| 700 |
1 |
0 |
|a McGuire, D.K.
|e author
|
| 700 |
1 |
0 |
|a on behalf of the VERTIS CV Investigators
|e author
|
| 700 |
1 |
0 |
|a Pong, A.
|e author
|
| 700 |
1 |
0 |
|a Pratley, R.
|e author
|
| 700 |
1 |
0 |
|a Shih, W.J.
|e author
|
| 773 |
|
|
|t Diabetologia
|
